Salīdzināt metodes
Apskatiet izvēlētās metodes blakus; rindas, kas atšķiras, ir izceltas.
| Daudzcentru IV fāzes pētījums× | Pētījuma IV fāze× | |
|---|---|---|
| Nozare | Epidemioloģija | Epidemioloģija |
| Saime | Process / pipeline | Process / pipeline |
| Izcelsmes gads≠ | 1980s–1990s (formalized with post-marketing requirements in modern drug regulation) | Formalised 1970s–1990s (ICH E3 guideline 1994) |
| Autors≠ | Regulatory agencies and pharmaceutical industry (ICH E2E, FDA, EMA post-marketing frameworks) | Regulatory agencies and pharmaceutical industry (ICH, FDA, EMA frameworks) |
| Tips≠ | Observational or interventional post-marketing study | Post-marketing observational or interventional study |
| Pirmavots≠ | Strom, B. L., & Kimmel, S. E. (Eds.). (2005). Textbook of Pharmacoepidemiology. John Wiley & Sons. ISBN: 978-0470029619 | International Conference on Harmonisation (ICH). (1994). ICH Harmonised Tripartite Guideline: Structure and Content of Clinical Study Reports E3. ICH Secretariat. link ↗ |
| Citi nosaukumi | multicenter post-marketing study, multicenter pharmacovigilance study, multi-site phase IV study, post-authorization safety study | post-marketing surveillance study, post-approval study, Phase 4 study, PMS study |
| Saistītās≠ | 6 | 5 |
| Kopsavilkums≠ | A multicenter Phase IV study is a post-marketing surveillance investigation conducted simultaneously at two or more clinical or research sites after a drug, device, or intervention has received regulatory approval. By pooling real-world data from diverse patient populations and geographic regions, it detects rare adverse events, evaluates long-term effectiveness, characterizes safety in subgroups, and fulfills regulatory post-authorization commitments that single-site studies cannot achieve. | A Phase IV study is a post-marketing surveillance study conducted after a drug, device, or intervention has received regulatory approval. Its primary purpose is to monitor long-term safety, detect rare adverse events, assess effectiveness in routine clinical practice, and explore new indications or populations not adequately represented in earlier trials. Phase IV evidence accumulates continuously throughout a product's commercial life. |
| ScholarGateDatu kopa ↗ |
|
|